Effect of centrally administered encephalinamides on regional cerebral blood flow in the dog

Jeffrey Kirsch, D. F. Hanley, D. A. Wilson, R. J. Traystman

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

(D-ala2)-met5-encephalinamide (AM encephalinamide) and (D-ala2)-leu5-encephalinamide (AL encephalinamide) were administered into the cisterna magna in anesthetized dogs to determine whether these opiates effected the neurohypophyseal circulation differently than the circulation of other brain areas. At the beginning of the experimental protocol, animals were given either mock cerebral spinal fluid (CSF) or 5 to 25 mg of AM encephalinamide or 5 mg of AL encephalinamide in equal volumes of mock CSF into the cisterna magna. By 60 min after intracisternal injection, radiolabeled AM encephalinamide distributed throughout the brain with the highest concentration being in the area of the brainstem. Sixty minutes after intracisternal injection, heart rate was decreased 29.0 ± 5.1%, 41.3 ± 4.4%, and 36.0 ± 3.6%, and MABP was decreased 25.2 ± 80.0%, 26.4 ± 2.4%, and 32.3 ± 2.6% in animals treated with AL encephalinamide (5 mg), AM encephalinamide (5 mg), and AM encephalinamide (25 mg), respectively. Neither AL encephalinamide nor AM encephalinamide altered CBF or CMRO2 when compared with animals treated with mock CSF, whereas both AL encephalinamide and AM encephalinamide reduced neurohypophyseal blood flow by 30 min (43 ± 11%, AL encephalinamide; 35 ± 7%, AM encephalinamide, 5 mg; 46 ± 8%, AM encephalinamide, 25 mg); the reduction was sustained throughout the 60-min protocol (34 ± 10%, AL encephalinamide; 37 ± 3%, AM encephalinamide, 5 mg; 38 ± 4% AM encephalinamide, 25 mg). Plasma arginine vasopressin was transiently elevated 15 (326 ± 75%, AL encephalinamide; 323 ± 109%, AM encephalinamide, 25 mg) and 30 min (271 ± 68%, AL encephalinamide; 368 ± 136%, AM encephalinamide, 25 mg) in animals treated with AL encephalinamide or AM encephalinamide (25 mg). Intravenous naloxone administered at the end of the 60-min encephalinamide protocol was associated with a rise toward control values in heart rate and MABP in the AL encephalinamide group and in heart rate, MABP, and neurohypophyseal blood flow in both the AM encephalinamide 5 mg and 25 mg groups. These data suggest that encephalinamides play a role in the regulation of neurohypophyseal blood flow through their actions on opiate receptors.

Original languageEnglish (US)
Pages (from-to)385-394
Number of pages10
JournalJournal of Cerebral Blood Flow and Metabolism
Volume8
Issue number3
StatePublished - 1988
Externally publishedYes

Fingerprint

Cerebrovascular Circulation
Regional Blood Flow
Dogs
Cisterna Magna
Heart Rate
Opiate Alkaloids
Injections
Arginine Vasopressin
Brain
Opioid Receptors
Naloxone
Brain Stem

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Neuroscience(all)

Cite this

Effect of centrally administered encephalinamides on regional cerebral blood flow in the dog. / Kirsch, Jeffrey; Hanley, D. F.; Wilson, D. A.; Traystman, R. J.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 8, No. 3, 1988, p. 385-394.

Research output: Contribution to journalArticle

@article{5c7cbd36c8ad4462bb5cfb887e11f66c,
title = "Effect of centrally administered encephalinamides on regional cerebral blood flow in the dog",
abstract = "(D-ala2)-met5-encephalinamide (AM encephalinamide) and (D-ala2)-leu5-encephalinamide (AL encephalinamide) were administered into the cisterna magna in anesthetized dogs to determine whether these opiates effected the neurohypophyseal circulation differently than the circulation of other brain areas. At the beginning of the experimental protocol, animals were given either mock cerebral spinal fluid (CSF) or 5 to 25 mg of AM encephalinamide or 5 mg of AL encephalinamide in equal volumes of mock CSF into the cisterna magna. By 60 min after intracisternal injection, radiolabeled AM encephalinamide distributed throughout the brain with the highest concentration being in the area of the brainstem. Sixty minutes after intracisternal injection, heart rate was decreased 29.0 ± 5.1{\%}, 41.3 ± 4.4{\%}, and 36.0 ± 3.6{\%}, and MABP was decreased 25.2 ± 80.0{\%}, 26.4 ± 2.4{\%}, and 32.3 ± 2.6{\%} in animals treated with AL encephalinamide (5 mg), AM encephalinamide (5 mg), and AM encephalinamide (25 mg), respectively. Neither AL encephalinamide nor AM encephalinamide altered CBF or CMRO2 when compared with animals treated with mock CSF, whereas both AL encephalinamide and AM encephalinamide reduced neurohypophyseal blood flow by 30 min (43 ± 11{\%}, AL encephalinamide; 35 ± 7{\%}, AM encephalinamide, 5 mg; 46 ± 8{\%}, AM encephalinamide, 25 mg); the reduction was sustained throughout the 60-min protocol (34 ± 10{\%}, AL encephalinamide; 37 ± 3{\%}, AM encephalinamide, 5 mg; 38 ± 4{\%} AM encephalinamide, 25 mg). Plasma arginine vasopressin was transiently elevated 15 (326 ± 75{\%}, AL encephalinamide; 323 ± 109{\%}, AM encephalinamide, 25 mg) and 30 min (271 ± 68{\%}, AL encephalinamide; 368 ± 136{\%}, AM encephalinamide, 25 mg) in animals treated with AL encephalinamide or AM encephalinamide (25 mg). Intravenous naloxone administered at the end of the 60-min encephalinamide protocol was associated with a rise toward control values in heart rate and MABP in the AL encephalinamide group and in heart rate, MABP, and neurohypophyseal blood flow in both the AM encephalinamide 5 mg and 25 mg groups. These data suggest that encephalinamides play a role in the regulation of neurohypophyseal blood flow through their actions on opiate receptors.",
author = "Jeffrey Kirsch and Hanley, {D. F.} and Wilson, {D. A.} and Traystman, {R. J.}",
year = "1988",
language = "English (US)",
volume = "8",
pages = "385--394",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Effect of centrally administered encephalinamides on regional cerebral blood flow in the dog

AU - Kirsch, Jeffrey

AU - Hanley, D. F.

AU - Wilson, D. A.

AU - Traystman, R. J.

PY - 1988

Y1 - 1988

N2 - (D-ala2)-met5-encephalinamide (AM encephalinamide) and (D-ala2)-leu5-encephalinamide (AL encephalinamide) were administered into the cisterna magna in anesthetized dogs to determine whether these opiates effected the neurohypophyseal circulation differently than the circulation of other brain areas. At the beginning of the experimental protocol, animals were given either mock cerebral spinal fluid (CSF) or 5 to 25 mg of AM encephalinamide or 5 mg of AL encephalinamide in equal volumes of mock CSF into the cisterna magna. By 60 min after intracisternal injection, radiolabeled AM encephalinamide distributed throughout the brain with the highest concentration being in the area of the brainstem. Sixty minutes after intracisternal injection, heart rate was decreased 29.0 ± 5.1%, 41.3 ± 4.4%, and 36.0 ± 3.6%, and MABP was decreased 25.2 ± 80.0%, 26.4 ± 2.4%, and 32.3 ± 2.6% in animals treated with AL encephalinamide (5 mg), AM encephalinamide (5 mg), and AM encephalinamide (25 mg), respectively. Neither AL encephalinamide nor AM encephalinamide altered CBF or CMRO2 when compared with animals treated with mock CSF, whereas both AL encephalinamide and AM encephalinamide reduced neurohypophyseal blood flow by 30 min (43 ± 11%, AL encephalinamide; 35 ± 7%, AM encephalinamide, 5 mg; 46 ± 8%, AM encephalinamide, 25 mg); the reduction was sustained throughout the 60-min protocol (34 ± 10%, AL encephalinamide; 37 ± 3%, AM encephalinamide, 5 mg; 38 ± 4% AM encephalinamide, 25 mg). Plasma arginine vasopressin was transiently elevated 15 (326 ± 75%, AL encephalinamide; 323 ± 109%, AM encephalinamide, 25 mg) and 30 min (271 ± 68%, AL encephalinamide; 368 ± 136%, AM encephalinamide, 25 mg) in animals treated with AL encephalinamide or AM encephalinamide (25 mg). Intravenous naloxone administered at the end of the 60-min encephalinamide protocol was associated with a rise toward control values in heart rate and MABP in the AL encephalinamide group and in heart rate, MABP, and neurohypophyseal blood flow in both the AM encephalinamide 5 mg and 25 mg groups. These data suggest that encephalinamides play a role in the regulation of neurohypophyseal blood flow through their actions on opiate receptors.

AB - (D-ala2)-met5-encephalinamide (AM encephalinamide) and (D-ala2)-leu5-encephalinamide (AL encephalinamide) were administered into the cisterna magna in anesthetized dogs to determine whether these opiates effected the neurohypophyseal circulation differently than the circulation of other brain areas. At the beginning of the experimental protocol, animals were given either mock cerebral spinal fluid (CSF) or 5 to 25 mg of AM encephalinamide or 5 mg of AL encephalinamide in equal volumes of mock CSF into the cisterna magna. By 60 min after intracisternal injection, radiolabeled AM encephalinamide distributed throughout the brain with the highest concentration being in the area of the brainstem. Sixty minutes after intracisternal injection, heart rate was decreased 29.0 ± 5.1%, 41.3 ± 4.4%, and 36.0 ± 3.6%, and MABP was decreased 25.2 ± 80.0%, 26.4 ± 2.4%, and 32.3 ± 2.6% in animals treated with AL encephalinamide (5 mg), AM encephalinamide (5 mg), and AM encephalinamide (25 mg), respectively. Neither AL encephalinamide nor AM encephalinamide altered CBF or CMRO2 when compared with animals treated with mock CSF, whereas both AL encephalinamide and AM encephalinamide reduced neurohypophyseal blood flow by 30 min (43 ± 11%, AL encephalinamide; 35 ± 7%, AM encephalinamide, 5 mg; 46 ± 8%, AM encephalinamide, 25 mg); the reduction was sustained throughout the 60-min protocol (34 ± 10%, AL encephalinamide; 37 ± 3%, AM encephalinamide, 5 mg; 38 ± 4% AM encephalinamide, 25 mg). Plasma arginine vasopressin was transiently elevated 15 (326 ± 75%, AL encephalinamide; 323 ± 109%, AM encephalinamide, 25 mg) and 30 min (271 ± 68%, AL encephalinamide; 368 ± 136%, AM encephalinamide, 25 mg) in animals treated with AL encephalinamide or AM encephalinamide (25 mg). Intravenous naloxone administered at the end of the 60-min encephalinamide protocol was associated with a rise toward control values in heart rate and MABP in the AL encephalinamide group and in heart rate, MABP, and neurohypophyseal blood flow in both the AM encephalinamide 5 mg and 25 mg groups. These data suggest that encephalinamides play a role in the regulation of neurohypophyseal blood flow through their actions on opiate receptors.

UR - http://www.scopus.com/inward/record.url?scp=0023899420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023899420&partnerID=8YFLogxK

M3 - Article

C2 - 3366800

AN - SCOPUS:0023899420

VL - 8

SP - 385

EP - 394

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 3

ER -